GKOS:NYE-Glaukos Corporation (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 117.17

Change

-0.72 (-0.61)%

Market Cap

USD 1.10B

Volume

0.84M

Analyst Target

USD 48.89
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-31 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

N/A

USD 198.11B
MDT Medtronic PLC

N/A

USD 113.61B
STE STERIS plc

N/A

USD 23.65B
ZBH Zimmer Biomet Holdings Inc

N/A

USD 21.34B
SNN Smith & Nephew SNATS Inc

N/A

USD 13.45B
GMED Globus Medical

N/A

USD 9.84B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.18B
BIO Bio-Rad Laboratories Inc

N/A

USD 9.18B
PEN Penumbra Inc

N/A

USD 7.86B
INSP Inspire Medical Systems Inc

N/A

USD 5.88B

ETFs Containing GKOS

AWEG The Alger ETF Trust 6.28 % 0.00 %

N/A

USD 4.69M
PSCH Invesco S&P SmallCap Heal.. 4.78 % 0.29 %

N/A

USD 0.20B
XSMO Invesco S&P SmallCap Mome.. 2.24 % 0.39 %

N/A

USD 1.24B
XHE SPDR® S&P Health Care Eq.. 1.97 % 0.35 %

N/A

USD 0.23B
VIOG Vanguard S&P Small-Cap 60.. 0.98 % 0.20 %

N/A

USD 0.99B
ESIX SPDR S&P SmallCap 600 ESG.. 0.78 % 0.00 %

N/A

USD 5.50M
CBUSAS:SW Amundi S&P SmallCap 600 E.. 0.75 % 0.00 %

N/A

N/A
SPSM SPDR® Portfolio S&P 600 .. 0.52 % 0.06 %

N/A

USD 11.12B
SAA ProShares Ultra SmallCap6.. 0.36 % 0.95 %

N/A

USD 0.04B
ETHO Amplify ETF Trust 0.00 % 0.45 %

N/A

USD 0.18B
SLYG SPDR® S&P 600 Small Cap .. 0.00 % 0.15 %

N/A

N/A
VIOO Vanguard S&P Small-Cap 60.. 0.00 % 0.15 %

N/A

N/A
ISP6:LSE iShares III Public Limite.. 0.00 % 0.00 %

N/A

USD 1.97B
BBSC JPMorgan BetaBuilders U.S.. 0.00 % 0.00 %

N/A

USD 0.51B
QVMS Invesco Exchange-Traded F.. 0.00 % 0.00 %

N/A

USD 0.20B
WELP:LSE HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 47.40% 91% A- 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 47.40% 91% A- 96% N/A
Trailing 12 Months  
Capital Gain 56.81% 90% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.81% 90% A- 95% A
Trailing 5 Years  
Capital Gain 44.51% 75% C 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.51% 75% C 64% D
Average Annual (5 Year Horizon)  
Capital Gain 25.42% 84% B 87% B+
Dividend Return 25.42% 84% B 86% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 53.64% 26% F 16% F
Risk Adjusted Return 47.39% 84% B 66% D+
Market Capitalization 1.10B 69% C- 82% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 42.30 26% 6%
Price/Book Ratio 10.52 11% 7%
Price / Cash Flow Ratio -114.17 100% 98%
Price/Free Cash Flow Ratio -60.25 97% 97%
Management Effectiveness  
Return on Equity -29.37% 25% 13%
Return on Invested Capital -16.66% 34% 10%
Return on Assets -7.95% 48% 10%
Debt to Equity Ratio 61.24% 32% 55%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector